Playback speed
10 seconds
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis
By
National Jewish Health
FEATURING
Rebecca Keith
By
National Jewish Health
FEATURING
Rebecca Keith
431 views
June 23, 2022
Please join Dr. Rebecca Keith pulmonologist at National Jewish Health and is an Associate Professor ...
read more ↘ in the Department of Medicine, Division of Pulmonary, Critical Care & Sleep Medicine, and Interstitial Lung Disease Program discussing the article “Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. N Engl J Med. 2022 May 15. doi: 10.1056/NEJMoa2201737. Epub ahead of print. PMID: 35569036” Here is the link to the journal article https://www.nationaljewish.org/education/pro-ed/live-events/national-jewish-health-journal-clubs/pdfs/njh-ild-june-article-summary.aspx
↖ read less
read more ↘ in the Department of Medicine, Division of Pulmonary, Critical Care & Sleep Medicine, and Interstitial Lung Disease Program discussing the article “Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. N Engl J Med. 2022 May 15. doi: 10.1056/NEJMoa2201737. Epub ahead of print. PMID: 35569036” Here is the link to the journal article https://www.nationaljewish.org/education/pro-ed/live-events/national-jewish-health-journal-clubs/pdfs/njh-ild-june-article-summary.aspx
↖ read less
Login to view comments.
Click here to Login